Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition

Amplification of the MYCN oncogene occurs in approximately 25% of primary neuroblastomas and is the single most powerful biological marker of poor prognosis in this disease. MYCN transcriptionally regulates a range of biological processes important for cancer, including cell metabolism. The MYCN-reg...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncogene
Auteurs principaux: Khan, Aaminah, Valli, Emanuele, Lam, Hayley, Scott, David A., Murray, Jayne, Eden, Georgina, Gamble, Laura D., Pandher, Rupinder, Flemming, Claudia L., Allan, Sophie, Osterman, Andrei L., Haber, Michelle, Norris, Murray D., Fletcher, Jamie I., Yu, Denise M.T.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970707/
https://ncbi.nlm.nih.gov/pubmed/32123312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-020-1235-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires